Relation between alkaline phosphatase, serum phosphate, and all-cause or cardiovascular mortality

Circulation

Volumn 120, Issue 18, 2009, Pages 1784-1792

  Tonelli, Marcello ^a,b   Curhan, Gary ^c   Pfeffer, Marc ^h   Sacks, Frank ^e   Thadhani, Ravi ^f   Melamed, Michal L ^g   Wiebe, Natasha ^a   Muntner, Paul ^d  

^a Department of Medicine ^*  (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c CHANNING LABORATORY   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

^g ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^h MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiovascular diseases; Cohort studies; Kidney failure, chronic; Metabolism; Myocardial infarction

Indexed keywords

ACETYLSALICYLIC ACID; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GAMMA GLUTAMYLTRANSFERASE; PHOSPHATE; PRAVASTATIN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD SAMPLING; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL;

ALKALINE PHOSPHATASE; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; DATA COLLECTION; FEMALE; HUMANS; KIDNEY DISEASES; MALE; MIDDLE AGED; MORTALITY; MYOCARDIAL INFARCTION; PHOSPHORIC MONOESTER HYDROLASES; SURVIVORS;

EID: 70449411188     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.109.851873     Document Type: Article

References (31)

1. Block GA, Raggi P, Bellasi A, Kooienga L, Spiegel DM. Mortality effect of coronary calcification and phosphate binder choice in incident hemo-dialysis patients. Kidney Int. 2007;71:438-441.
2. Foley RN, Parfrey PS. Cardiovascular disease and mortality in ESRD. J Nephrol. 1998;11:239-245.
3. Slinin Y, Foley RN, Collins AJ. Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: the USRDS Waves 1, 3, and 4 study. J Am Soc Nephrol. 2005;16:1788-1793.
4. Block GA, Port FK. Re-evaluation of risks associated with hyperphos-phatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management. Am J Kidney Dis. 2000;35:1226-1237.
5. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42:S1-S201.
6. Kestenbaum B, Sampson JN, Rudser KD, Patterson DJ, Seliger SL, Young B, Sherrard DJ, Andress DL. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol. 2005;16:520-528.
7. Dhingra R, Sullivan LM, Fox CS, Wang TJ, D'Agostino RB Sr, Gaziano JM, Vasan RS. Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. Arch Intern Med. 2007;167:879-885.
8. Tonelli M, Sacks F, Pfeffer M, Gao Z, Curhan G. Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation. 2005;112:2627-2633.
9. Abbott RD, Ueshima H, Masaki KH, Willcox BJ, Rodriguez BL, Ikeda A, Yano K, White LR, Curb JD. Coronary artery calcification and total mortality in elderly men. J Am Geriatr Soc. 2007;55:1948-1954. (Pubitemid 350230960)
10. Budoff MJ, Shaw LJ, Liu ST, Weinstein SR, Mosler TP, Tseng PH, Flores FR, Callister TQ, Raggi, Berman DS. Long-term prognosis associated with coronary calcification: observations from a registry of 25,253 patients. J Am Coll Cardiol. 2007;49:1860-1870.
11. Johnson R, Leopold J, Loscalzo J. Vascular calcification: pathobiological mechanisms and clinical implications. Circ Res. 2006;99:1044-1059.
12. Schoppet M, Shanahan CM. Role for alkaline phosphatase as an inducer of vascular calcification in renal failure? Kidney Int. 2008;73:989-991.
13. Harmey D, Hessle L, Narisawa S, Johnson KA, Terkeltaub R, Millán JL. Concerted regulation of inorganic pyrophosphate and osteopontin by akp2, enpp1, and ank: an integrated model of the pathogenesis of mineralization disorders. Am J Pathol. 2004;164:1199-1209.
14. Blayney MJ, Pisoni RL, Bragg-Gresham JL, Bommer J, Piera L, Saito A, Akiba T, Keen ML, Young EW, Port FK. High alkaline phosphatase levels in hemodialysis patients are associated with higher risk of hospi-talization and death. Kidney Int. 2008;74:655-663.
15. Regidor DL, Kovesdy CP, Mehrotra R, Rambod M, Jing J, McAllister CJ, Van Wyck D, Kopple JD, Kalantar-Zadeh K. Serum alkaline phosphatase predicts mortality among maintenance hemodialysis patients. J Am Soc Nephrol. 2008;19:2193-2203.
16. Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med. 2000;342:1478-1483.
17. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001.
18. Sacks FM, Pfeffer MA, Moye L, Brown LE, Hamm P, Cole TG, Hawkins CM, Braunwald E. Rationale and design of a secondary prevention trial of lowering normal plasma cholesterol levels after acute myocardial infarction: the Cholesterol and Recurrent Events trial (CARE). Am J Cardiol. 1991;68:1436.
19. Plan and operation of the Third National Health and Nutrition Examination Survey, 1988-1994: series 1: programs and collection procedures. Vital Health Stat 1. 1994 July 1-407.
20. Selvin E, Manzi J, Stevens LA, Van Lente F, Lacher DA, Levey AS, Coresh J. Calibration of serum creatinine in the National Health and Nutrition Examination Surveys (NHANES) 1988-1994, 1999-2004. Am J Kidney Dis. 2007;50:918-926.
21. NKF-K/DOQI clinical practice guidelines for chronic kidney disease. Am J Kidney Dis. 2002;39(suppl 1):S76.
22. Melamed ML, Michos ED, Post W, Astor B. 25-Hydroxyvitamin D levels and the risk of mortality in the general population. Arch Intern Med. 2008;168:1629-1637.
23. Loria CM, Sempos CT, Vuong C. Plan and operation of the NHANES II Mortality Study, 1992. Vital Health Stat 1. 1999 June:1-16.
24. Tonelli M, Sacks F, Arnold M, Moye L, Davis B, Pfeffer M. Relation between red blood cell distribution width and cardiovascular event rate in people with coronary disease. Circulation. 2008;117:163-168.
25. Menke A, Muntner P, Batuman V, Silbergeld EK, Guallar E. Blood lead below 0.48 /xmol/L (10 /xg/dL) and mortality among US adults. Circulation. 2006;114:1388-1394.
26. Harrell F. Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis. New York, NY: Springer-Verlag; 2001.
27. Palmer SC, McGregor DO, Macaskill P, Craig JC, Elder GJ, Strippoli GF. Meta-analysis: vitamin D compounds in chronic kidney disease. Ann Intern Med. 2007;147:840-853.
28. Lomashvili K, Garg P, Narisawa S, Millan J, O'Neill W. Upregulation of alkaline phosphatase and pyrophosphate hydrolysis: potential mechanism for uremic vascular calcification. Kidney Int. 2008;73:1024-1030.
29. Narang R, Ridout D, Nonis C, Kooner JS. Serum calcium, phosphorus and albumin levels in relation to the angiographic severity of coronary artery disease. Int J Cardiol. 1997;60:73-79.
30. Adeney K, Siscovick D, Ix J, Seliger S, Shlipak M, Jenny N, Kestenbaum B. Association of serum phosphate with vascular and valvular calcification in moderate CKD. J Am Soc Nephrol. 2009;20:381-387.
31. Gutiérrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, Smith K, Lee H, Thadhani R, Jüppner H, Wolf M. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med. 2008;359:584-592.